Angiotech Drug-Coated Stent Graft Clinical Trials To Commence In 2005
This article was originally published in The Gray Sheet
Executive Summary
Angiotech Pharmaceuticals aims to leverage its recent acquisition of STS Biopolymers to develop a non-coronary, drug-coated device line